FDA 483 - Teligent Pharma, Inc. - May 20, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Teligent Pharma, Inc. in Buena, NJ, a drug manufacturer, was cited for significant deficiencies across its quality control, production, and quality systems. The inspection revealed failures in rejecting out-of-specification drug products, inadequate investigations into stability failures, widespread issues with laboratory and production records, and non-adherence to stability testing programs and complaint handling procedures. Additionally, the firm failed to submit required NDA Field Alert Reports and complete annual product reviews, indicating systemic control issues.
ID · c9a36aa1-badb-42eb-afed-802e03b6b4e6